
	Where results make sense

Topic: Infliximab

Related Topics

Etanercept

Monoclonal antibody

Rheumatoid arthritis

Bone marrow transplant

Crohns disease

Tuberculosis

Central nervous system

Rheumatology

Azathioprine

Dairy

Lymphatic system

Steroid

In the News (Tue 22 Dec 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

	Infliximab - Wikipedia, the free encyclopedia
		Infliximab (Remicade®) is a powerful drug used to treat auto-immune disorders like Crohn's disease and rheumatoid arthritis.
		Infliximab is known as a "chimeric monoclonal antibody" (the term "chimeric" refers to the use of both mouse and human components of the drug i.e.
		Before infliximab is administered a test for tuberculosis must be performed, as infliximab has been shown to increase the risk of reactivation of latent tuberculosis.
	en.wikipedia.org /wiki/Infliximab (326 words)

	Patient Education - Drugs - infliximab, Remicade
		Infliximab belongs to a new class of drugs known as monoclonal antibodies.
		Infliximab is used for the treatment of patients with moderate to severe Crohn's disease for whom conventional therapy has not been effective.
		The effect of infliximab in pediatric patients and the elderly is unknown.
	www.gicare.com /pated/infliximab.htm (849 words)

	infliximab (Remicade) - drug class, medical uses, medication side effects, and drug interactions by MedicineNet.com
		Specifically, infliximab is used for treating the inflammation of Crohn's disease, rheumatoid arthritis, and psoriatic arthritis.
		Infliximab does not cure Crohn's disease, psoriatic arthritis or rheumatoid arthritis; however, preliminary studies have demonstrated that infliximab can retard the destruction of joints by rheumatoid arthritis.
		PRESCRIBED FOR: Infliximab is approved for use alone or combined with methotrexate for treating moderate to severe rheumatoid arthritis. Infliximab is also used for reducing the signs and symptoms of inflammation in moderate to severe Crohn's disease and Crohn's disease in which there are fistulas (passageways created when the inflammation penetrates beyond the wall of the intestine).
	www.medicinenet.com /infliximab/article.htm (830 words)

	INFLIXIMAB (Site not responding. Last check: 2007-10-20)
		Infliximab is indicated in the treatment of moderately to severely active Crohn's disease for the reduction of signs and symptoms in patients who have had an inadequate response to conventional therapy; or
		Infliximab is indicated in the treatment of patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous fistula(s); or
		Infliximab should not be used with patients who have a history of sensitivity to any murine (mouse) proteins.
	www.gamedicare.com /Policies/318.1.htm (1138 words)

	Infliximab for Crohn's disease - [Medication] (Site not responding. Last check: 2007-10-20)
		Infliximab is an antibody that inhibits tumour necrosis factor, a protein that increases inflammation in the body.
		Infliximab is used to treat abnormal connections (fistulas) between the intestines and organs in moderate to severe Crohn's disease.
		Infliximab may increase your risk of cancer of the lymph glands (lymphoma).
	www.bchealthguide.org /kbase/topic/detail/drug/tw2242/detail.htm (627 words)

	Hospital Practice: Crohn's Disease (Site not responding. Last check: 2007-10-20)
		Infliximab is a chimeric monoclonal antibody against tumor necrosis factor-alpha.
		Based on those data, the FDA approved the use of infliximab as a single infusion for chronically active disease or as a series of infusions for fistula.
		Infliximab, a potent inhibitor of tumor necrosis factor-alpha, has been shown to be effective in inducing remission in patients refractory to other therapies.
	www.hosppract.com /issues/1999/08/dmmhan.htm (3799 words)

	Drugs for Arthritis -- Infliximab
		Infliximab (trade name Remicade) is a type of drug known as anti-TNF.
		Infliximab is given by intravenous infusion (that is, through a drip into a vein).
		Infliximab may cause a blocked or runny nose, headache, dizziness, flushing, rash, abdominal pain or indigestion.
	www.poolehos.org /rheum/infliximab.html (746 words)

	Infliximab
		Infliximab is used to reduce the signs and symptoms of rheumatoid arthritis and improve physical function of the joints.
		Infliximab is only used to reduce the inflammation of the intestines in severe Crohn's disease when other treatment has been ineffective.
		Infliximab is only given under the supervision of specialists in rheumatoid arthritis or inflammatory bowel diseases.
	www.tiscali.co.uk /lifestyle/healthfitness/health_advice/netdoctor/archive/100004617.html (1112 words)

	Infliximab
		Infliximab decreases the inflammation in the gastrointestinal tract where the Crohn's disease is active.
		Mixing the infliximab with another liquid and giving it into the vein is a type of infusion.
		Infliximab will be given in a clinic or hospital setting under close observation.
	www.umm.edu /altmed/ConsDrugs/Infliximabcd.html (659 words)

	CCFA.org: Infliximab Approved for Ulcerative Colitis
		Infliximab is currently the only biologic indicated for the treatment of both Crohn's and colitis, the major forms of inflammatory bowel disease (IBD).
		The decision to use infliximab for this disease is complex and will be based on a number of factors, including a patient's response to other therapies.
		Infliximab was first approved in the United States for the treatment of Crohn's disease in 1998 and is also indicated for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.
	www.ccfa.org /about/news/infliximabforuc (514 words)

	Remicade Side Effects, and Drug Interactions - Infliximab - RxList ...
		The incidence of antibodies to infliximab in patients given a 3-dose induction regimen followed by maintenance dosing was approximately 10% as assessed through 1 to 2 years of REMICADE treatment.
		The data reflect the percentage of patients whose test results were positive for antibodies to infliximab in an ELISA assay, and are highly dependent on the sensitivity and specificity of the assay.
		Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn’s disease including corticosteroids, antibiotics (metronidazole or ciprofloxacin) and aminosalicylates.
	www.rxlist.com /cgi/generic3/infliximab_ad.htm (2029 words)

	Infliximab - Wikipedia, the free encyclopedia
		Infliximab is known as a "chimeric monoclonal antibody" (the term "chimeric" refers to the use of mouse genes as a component of the drug).
		The drug reduces the amount of active TNF-α (tumour necrosis factor alpha) in the body.
		After a number of studies and reports of significant adverse reactions in patients receiving infliximab therapy (including serious and sometimes fatal blood disorders, infections, and central nervous system disorders), the U.S. Food and Drug Administration issued a warning to doctors instructing them to screen and monitor potential patients more carefully.
	www.encyclopedia-online.info /Remicade (220 words)

	Infliximab - Drugs & Vitamins - Drug Library - DrugDigest
		INFLIXIMAB (Remicade®) is used to help relieve the symptoms of Crohn's disease, psoriasis, or rheumatoid arthritis.
		It is important to receive infliximab on the schedule developed by your health care provider.
		Infliximab may worsen the symptoms of heart failure in some patients.
	www.drugdigest.org /DD/DVH/Uses/0,3915,772\|Infliximab,00.html (559 words)

	Infliximab (Site not responding. Last check: 2007-10-20)
		Infliximab (Remicaide in USA) / (Revellex in South Africa), is a Chimeric antibody including human and mouse component.It acts by blocking the molecular system that drives the immune response - Tumour necrosis factor.
		Infliximab is an antibody designed to bind to TNF that is in circulation, thereby preventing TNF from binding to the surface receptors and hence preventing the immune response.
		Of the estimated 554372 patient years experience on infliximab there are increased numbers of TB reported.
	www.arthritis.co.za /infliximab.html (1040 words)

	Infliximab shows efficacy in treatment of ulcerative colitis
		Infliximab is the first biologic to show efficacy in two inflammatory bowel diseases (IBD), Crohn's Disease and ulcerative colitis.
		The ACT 1 and ACT 2 clinical trials were conducted to evaluate the safety and efficacy of Infliximab 5 mg/kg and 10 mg/kg at weeks zero, two and six and then every eight weeks in people with active ulcerative colitis.
		The proportion of patients who were able to discontinue corticosteroids while in clinical remission at week 30 was significantly greater in both Infliximab groups compared with the placebo group (18 percent, 5 mg/kg; 27 percent, 10 mg/kg; 3 percent, placebo; P=0.010 and P 0.001, respectively).
	www.xagena.it /news/medicinenews_net_news/2db9f30839751e6714522e71cdad18b5.html (935 words)

	Arthritis Research Campaign \| Anti-TNF therapy (etanercept, infliximab and adalimumab) (Site not responding. Last check: 2007-10-20)
		Etanercept is currently prescribable for both children and adults, whereas infliximab must be prescribed with methotrexate and is only licensed for the treatment of adults.
		Infliximab is now also licensed for ankylosing spondylitis.
		Infliximab is given via an infusion (drip) in hospital at regular intervals.
	www.arc.org.uk /newsviews/anti_tnf.htm (559 words)

	Anti-TNF for ankylosing spondylitis [December 2002; 106-2]
		Intravenous infliximab was infused at 5 mg/kg at the start of the study and at two and six weeks.
		The primary outcome was achieved by 17/34 patients on infliximab and 2/35 on placebo, and the difference between placebo and infliximab was apparent by the second week.
		Three patients on infliximab had serious events and were withdrawn due to emergent tuberculosis, fever, and transient leucopenia.
	www.jr2.ox.ac.uk /bandolier/band106/b106-2.html (1361 words)

	MedlinePlus Drug Information: Infliximab (Systemic) (Site not responding. Last check: 2007-10-20)
		Infliximab is also used to treat ulcerative colitis.
		Infliximab is usually given by a doctor or nurse.
		Infliximab may cause chest pain, fever, chills, itching, hives, flushing of face, or troubled breathing within a few hours after you receive it.
	www.nlm.nih.gov /medlineplus/druginfo/uspdi/203667.html (1235 words)

	NEJM -- Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
		Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations.
		Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit.
		Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study.
	content.nejm.org /cgi/content/abstract/343/22/1594 (5220 words)

	infliximab, Primary Sclerosing Cholangitis Literature
		Chey WY, Shah A 2005 Infliximab for ulcerative colitis.
		Konrad A, Seibold F 2003 Response of cutaneous Crohn's disease to infliximab and methotrexate.
		Mouser JF, Hyams JS 1999 Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn's disease.
	www.psc-literature.org /inflix.htm (9900 words)

	Infliximab (Remicade). DermNet NZ
		However, recent clinical trials of infliximab for the treatment of psoriasis and psoriatic arthritis are proving it to be an effective treatment for these conditions.
		For the treatment of psoriasis and psoriatic arthritis, infliximab is administered by intravenous infusion under specialist supervision.
		Infliximab is usually given in combination with methotrexate, which helps to prevent the formation of anti-infliximab antibodies.
	www.dermnetnz.org /treatments/infliximab.html (443 words)

	Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease -- ten Hove et al. 50 (2): ...
		Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease -- ten Hove et al.
		We observed that infliximab induced apoptosis and an increase
		Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.
	gut.bmjjournals.com /cgi/content/full/50/2/206 (4503 words)

	Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease -- Sandborn and Loftus 53 ...
		Infliximab, a monoclonal antibody to tumour necrosis factor
		Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.
		Infliximab for Crohn’s disease in clinical practice at the Mayo Clinic: the first 100 patients.
	www.gutjnl.com /cgi/content/full/53/6/780 (2114 words)

	Maintenance Infliximab for Fistulizing Crohn Disease - Journal Watch Gastroenterology
		Infliximab is effective as maintenance therapy for patients
		of fistulas occurred in 16% and 22% of infliximab and placebo
		One patient in the infliximab group developed a lupus-like syndrome.
	gastro.jwatch.org /cgi/content/full/2004/317/1 (367 words)

	NEJM -- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor {alpha}-Neutralizing Agent
		Chronic myeloid leukaemia and tuberculosis in a patient with rheumatoid arthritis treated with infliximab.
		Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County.
		Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate.
	content.nejm.org /cgi/content/abstract/345/15/1098 (3845 words)

	Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists -- Scallon et al. 301 (2): 418 -- ...
		Infliximab or etanercept was mixed with 1 µg/ml human TNF at 10:1 or 30:1 M ratios in HUVE cell medium and incubated for 30
		Each molecule of infliximab is believed to be able to bind either one or two molecules of trimeric and/or monomeric tmTNF, and up to three molecules of infliximab are believed to bind each tmTNF trimer, leaving few or no receptor binding sites free when infliximab is present in excess.
		The variable regions of infliximab are indicated in purple and the p75 TNF receptor portion of etanercept is indicated in dark blue.
	jpet.aspetjournals.org /cgi/content/full/301/2/418 (6589 words)

	Remicade infliximab side effects, tuberculosis lawyer (Site not responding. Last check: 2007-10-20)
		Remicade (Infliximab), an immune-suppressing drug used to treat rheumatoid arthritis and Crohn's disease, has been linked to causing 70 reported cases of tuberculosis (TB) among US patients.
		Researchers who reviewed the cases say that the immune-system protein infliximab suppresses--called tumor necrosis factor alpha (TNF-alpha)--appears to be key in controlling TB infection.
		In August, Malvern, Pennsylvania-based Centocor, which markets infliximab as Remicade, announced it was changing the drug's prescribing information to address the TB concerns.
	www.remicade-side-effects.com (265 words)

Try your search on: Qwika (all wikis)